Grace Therapeutics, Inc.
GRCE
$2.72
-$0.08-2.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.37M | -11.61M | -11.45M | -12.85M | -38.77M |
| Total Depreciation and Amortization | 6.00K | 5.00K | 5.00K | 11.00K | 18.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.79M | -2.53M | 107.00K | 1.79M | 26.82M |
| Change in Net Operating Assets | 1.11M | 2.31M | 1.65M | -1.28M | -1.63M |
| Cash from Operations | -14.04M | -11.82M | -9.69M | -12.33M | -13.57M |
| Capital Expenditure | -22.00K | -22.00K | -22.00K | -22.00K | -8.00K |
| Sale of Property, Plant, and Equipment | 1.00K | 1.00K | 111.00K | 111.00K | 110.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.57M | 0.00 | 0.00 | 15.00K | -1.55M |
| Cash from Investing | 6.55M | -21.00K | 89.00K | 104.00K | -1.45M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 7.36M | 7.36M | 7.36M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 0.00 | 7.36M | 7.36M | 7.36M |
| Foreign Exchange rate Adjustments | -- | -- | 2.00K | 0.00 | -32.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.49M | -11.84M | -2.24M | -4.87M | -7.70M |